This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lamers, K J. Articles by Jongen, P J. Search for Related Content PubMed PubMed Citation Articles by Lamers, K J. Articles by Jongen, P J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHYLPREDNISOLONE Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis

University Hospital Nijmegen, Institute of Neurology, Laboratory of Neurology, PO Box 9101, 6500 HB Nijmegen

H PM de Reus

University Hospital Nijmegen, Institute of Neurology, Laboratory of Neurology, PO Box 9101, 6500 HB Nijmegen

P JH Jongen

MS Center, Nijmegen, The Netherlands

There is an evident need for a quantitative laboratory marker for ascertaining disease activity and treatment effects in multiple sclerosis (MS) patients. Activity of the disease process in MS is accompanied by myelin breakdown and appearance of myelin basic protein (MBP) in cerebrospinal fluid (CSF). In this paper MBP in CSF of relapsing-remitting (RR) MS patients is reviewed. MBP in CSF is a fragment containing an epitope corresponding to aminoacid residues 45-89 of the native molecule. From several relevant studies about CSF MBP in RR MS the following relations can be concluded: CSF MBP levels in active MS patients are frequently increased (45-100%), remain increased until 5 to 6 weeks after onset symptoms and are higher in polysymptomatic exacerbations and correlate with number of gadolinium-enhanced (Gd) lesions on MRI, severity of relapses, EDSS score and CSF intrathecal IgM synthesis. After an intravenous methylprednisolone treatment the increased CSF MBP levels return to normal values and reduction in CSF MBP is related to reduction in EDSS score, number of Gd lesions and CSF intrathecal IgM synthesis.

Key Words: multiple sclerosis • cerebrospinal fluid • MBP • methylprednisolone

Multiple Sclerosis, Vol. 4, No. 3, 124-126 (1998)
DOI: 10.1177/135245859800400306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. F. de Vos, M. van Meurs, H. P. Brok, L. A. Boven, R. Q. Hintzen, P. van der Valk, R. Ravid, S. Rensing, L. Boon, B. A. 't Hart, et al. Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs J. Immunol., November 15, 2002; 169(10): 5415 - 5423. [Abstract] [Full Text] [PDF]

				K G Warren and I. Catz Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients Multiple Sclerosis, October 1, 2000; 6(5): 300 - 311. [Abstract] [PDF]